Navigation Links
Chipscreen and HUYA Bioscience to Present Clinical Data on Novel HDAC Inhibitor at the 2009 ASCO Annual Meeting
Date:5/28/2009

SHENZHEN, China and SAN DIEGO, May 28 /PRNewswire/ -- Shenzhen Chipscreen Biosciences, Ltd., and HUYA Bioscience International, LLC, today announced that final data from a Phase 1 trial conducted by Chipscreen of the investigational compound chidamide (CS055/HBI-8000) will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 29 to June 2, 2009, in Orlando, Florida. Chidamide/HBI-8000 is a novel benzamide class histone deacetylase (HDAC) inhibitor in development by Chipscreen and HUYA for oncology indications. The data to be presented will include safety, pharmacokinetics, and biomarker and anti-tumor activity (abstract #3529).

                  Title:  "Phase 1 study of chidamide (CS055/HBI-8000), a
                          novel histone deacetylase inhibitor, in patients
                          with advanced solid tumors and lymphomas"

    Poster Presentation:  Friday, May 29, 2 pm - 6 pm EDT, Level 3, W315A,
                          Board 13

      Poster Discussion:  Friday, May 29, 5 pm - 6 pm EDT, Level 4, Valencia
                          Room, W415D

Shenzhen Chipscreen Biosciences is a leading China-based biotechnology company that specializes in discovering and developing proprietary small molecule therapeutics for unmet medical needs. The company is utilizing its proprietary chemical genomics-based discovery platform to develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas. The core competence of the company is the science-driven approach in discovery, strong pipeline building capability, experience with IP, and regulatory expertise. Additional information about the company is available at www.chipscreen.com.

HUYA Bioscience International is a leader in enabling and accelerating the global co-development of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese academic and commercial biopharmaceutical organizations to enhance development efficiency and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for building and maximizing the worldwide value of biopharmaceutical innovation in China. HUYA is jointly headquartered in San Diego, CA, and Shanghai, PRC. Additional information about the company is available at www.huyabio.com.

    Contact:
      For Chipscreen:                   For HUYA:
      Sophie Cao, M.D.                  Michael Newman, Ph.D.
      Head of Medical Affairs           Executive Vice President, Oncology
      +86 755 26719670                  +1 858 798-8800
      +86 138 23171987 mobile           +1 858 922-9015 mobile

      Zhi-Qiang Ning, M.D., Ph.D.       Juliet Travis (media contact)
      Vice President, R&D               +1 510 452-3771
      +86 755 26957727
      +86 139 24590432 mobile


'/>"/>
SOURCE HUYA Bioscience International, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
11. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at www.diabetesscholars.org ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
(Date:6/23/2016)... , June 23, 2016 ... "Surgical Procedure Volumes: Global Analysis (United States, China, ... Canada)" report to their offering. ... essential tool for healthcare business planners, provides surgical procedure ... at surgery trends with an in-depth analysis of growth ...
Breaking Medicine Technology:
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream that ... dermaka cream can be incorporated into the post-surgical treatment plans of a variety of ... , dermaka cream is very effective for bruising and causes a rapid resolution of ...
(Date:6/24/2016)... Edwardsville, IL (PRWEB) , ... June 24, 2016 ... ... Darryll Beard, DDS, and Randall Markarian, DDS, are co-chairs for the Illinois State ... dental clinic Friday-Saturday, July 15-16 at the Gateway Convention Center in Collinsville. ...
(Date:6/24/2016)... ... June 24, 2016 , ... SpiritQuest Sedona Retreats, located in Arizona ... surrounded by famous vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new ... Lodge at Sedona as well as the Sedona Rouge, both popular accommodations for SpiritQuest ...
(Date:6/23/2016)... ... June 23, 2016 , ... Terumo BCT, a global ... for clinical transfusion research programs and for the blood supply in the Netherlands, ... Predictive Analytical Rating Score (PREPAReS) study. , Currently in its sixth year, ...
Breaking Medicine News(10 mins):